The BioPharm Brief: Deals, Data, and a $2 Billion Bet

Sep 29, 09:01 PM
Headliner
Share
Subscribe

Novo Nordisk licenses a once-weekly oral GLP-1/GIP candidate, uniQure reports 48-month Huntington’s disease data, and AstraZeneca invests $2 billion in Summit Therapeutics.

Share
Subscribe
Next
The BioPharm Brief: Weekly Insulin, Excipient Data, and the Fate of a Lung Cancer ADC
Top episodes
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
by The BioPharm Brief
The BioPharm Brief: Cancer, Personalized
by The BioPharm Brief
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
by The BioPharm Brief